Used primarily in pharmaceutical research, this compound functions as an immunomodulatory agent and is investigated for its potential in targeted protein degradation. It acts as a cereblon E3 ligase modulator, enabling the selective degradation of disease-related proteins. Due to this mechanism, it has gained significant interest in oncology drug development, particularly in therapies targeting hematological malignancies such as multiple myeloma and myelodysplastic syndromes. Its structure allows for enhanced binding affinity and specificity, making it a valuable scaffold in the design of novel proteolysis-targeting chimeras (PROTACs) and other bifunctional molecules. Additionally, the compound shows anti-inflammatory and anti-angiogenic properties, broadening its potential therapeutic applications.